Retatrutide (LY-3437943)
Retatrutide is a research grade peptide that is being studied in several clinical trials as a so-called triple agonist , with effects on the GIP, GLP-1 and glucagon receptors .
This unique combination is central to scientific research into energy metabolism, fat burning and appetite regulation .
Research findings
In Eli Lilly 's Phase 2 studies published in the New England Journal of Medicine (2023), subjects experienced a mean weight reduction of 17–24% over a period of 24–48 weeks (depending on dose and duration).
Researchers also saw improvements in metabolic markers , including a reduction in HbA1c in individuals with type 2 diabetes.
Further studies are currently investigating the long-term safety and mechanisms of effect of Retatrutide as a model for combined incretin agonists.
Research context
Retatrutide is used in laboratories and research institutions to analyze the effects of triple agonism on metabolism, fat oxidation and energy expenditure .
It is used only for in vitro research, reference standards , and preclinical research purposes .
Not developed or approved for medical, cosmetic or therapeutic use.
Important information
For laboratory research only
Not intended for human consumption or injection.
For research and development purposes only
Buyer is responsible for compliance with local laws and regulations
The seller is not liable for incorrect or improper use.
Sold out
Sold out
